Ria Arnold1, Timothy J Pianta2, Bruce A Pussell3,4, Adrienne Kirby5, Kate O'Brien6, Karen Sullivan6, Margaret Holyday6, Christine Cormack4, Matthew C Kiernan7, Arun V Krishnan8. 1. School of Medical Sciences and. 2. Northern Clinical School, University of Melbourne, Melbourne, Australia. 3. Departments of Nephrology and. 4. Prince of Wales Clinical School, UNSW Sydney, Sydney, Australia. 5. Nutrition and Dietetics, Prince of Wales Hospital, Sydney, Australia; and. 6. National Health and Medical Research Council Clinical Trials Centre and. 7. Brain and Mind Centre, University of Sydney, Sydney, Australia. 8. Nutrition and Dietetics, Prince of Wales Hospital, Sydney, Australia; and Arun.Krishnan@unsw.edu.au.
Abstract
BACKGROUND AND OBJECTIVES: Neuromuscular complications are almost universal in CKD by the time that a patient commences dialysis. Recent studies have indicated that chronic hyperkalemia may contribute to the development of neuropathy in CKD. This study was undertaken to determine whether dietary restriction of potassium intake may be a neuroprotective factor in CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A 24-month prospective, single-blind, randomized, controlled trial was undertaken in 47 consecutively recruited patients with stages 3 and 4 CKD. The intervention arm (n=23) was prescribed a diet focusing on potassium restriction to meet a monthly serum potassium level of ≤4.5 mEq/L, with oral sodium polystyrene sulfonate provided if dietary advice failed to achieve the target. The control arm (n=24) received dietary advice regarding general nutrition. The primary outcome was the change in the total neuropathy score evaluated by a blinded observer. Secondary outcomes included electrolyte levels, gait speed, neurophysiologic parameters, and health-related quality of life scores. Five patients withdrew before initiation of treatment, and final analysis consisted of n=21 in each group. RESULTS: There was a greater increase in total neuropathy score from baseline to final assessment in the control arm compared with the intervention arm (6.1±6.2-8.6±7.9 controls; 7.8±7.4-8.2±7.5 intervention; change 2.8±3.3-0.4±2.2, respectively; P<0.01). The intervention significantly reduced mean serum potassium compared with controls (4.6±0.1-4.8±0.1 mEq/L mean recorded every 6 months over the trial duration; P=0.03). There were no adverse changes in other nutritional parameters. Improved gait speed was also noted in the intervention arm compared with the control arm, with a mean increase of 0.15±0.17 m/s in the intervention group versus 0.02±0.16 m/s in the control group (P=0.01). CONCLUSIONS: Our results provide important preliminary evidence that dietary potassium restriction confers neuroprotection in CKD and should be confirmed in a larger multicenter trial.
RCT Entities:
BACKGROUND AND OBJECTIVES: Neuromuscular complications are almost universal in CKD by the time that a patient commences dialysis. Recent studies have indicated that chronic hyperkalemia may contribute to the development of neuropathy in CKD. This study was undertaken to determine whether dietary restriction of potassium intake may be a neuroprotective factor in CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A 24-month prospective, single-blind, randomized, controlled trial was undertaken in 47 consecutively recruited patients with stages 3 and 4 CKD. The intervention arm (n=23) was prescribed a diet focusing on potassium restriction to meet a monthly serum potassium level of ≤4.5 mEq/L, with oral sodium polystyrene sulfonate provided if dietary advice failed to achieve the target. The control arm (n=24) received dietary advice regarding general nutrition. The primary outcome was the change in the total neuropathy score evaluated by a blinded observer. Secondary outcomes included electrolyte levels, gait speed, neurophysiologic parameters, and health-related quality of life scores. Five patients withdrew before initiation of treatment, and final analysis consisted of n=21 in each group. RESULTS: There was a greater increase in total neuropathy score from baseline to final assessment in the control arm compared with the intervention arm (6.1±6.2-8.6±7.9 controls; 7.8±7.4-8.2±7.5 intervention; change 2.8±3.3-0.4±2.2, respectively; P<0.01). The intervention significantly reduced mean serum potassium compared with controls (4.6±0.1-4.8±0.1 mEq/L mean recorded every 6 months over the trial duration; P=0.03). There were no adverse changes in other nutritional parameters. Improved gait speed was also noted in the intervention arm compared with the control arm, with a mean increase of 0.15±0.17 m/s in the intervention group versus 0.02±0.16 m/s in the control group (P=0.01). CONCLUSIONS: Our results provide important preliminary evidence that dietary potassium restriction confers neuroprotection in CKD and should be confirmed in a larger multicenter trial.
Authors: Matthew C Kiernan; R Jon L Walters; Kjeld V Andersen; David Taube; Nicholas M F Murray; Hugh Bostock Journal: Brain Date: 2002-06 Impact factor: 13.501
Authors: Arun V Krishnan; Richard K S Phoon; Bruce A Pussell; John A Charlesworth; Hugh Bostock; Matthew C Kiernan Journal: Brain Date: 2005-06-09 Impact factor: 13.501
Authors: Baback Roshanravan; Cassianne Robinson-Cohen; Kushang V Patel; Ernest Ayers; Alyson J Littman; Ian H de Boer; T Alp Ikizler; Jonathan Himmelfarb; Leslie I Katzel; Bryan Kestenbaum; Stephen Seliger Journal: J Am Soc Nephrol Date: 2013-04-18 Impact factor: 10.121
Authors: Ria Arnold; Bruce A Pussell; Timothy J Pianta; Virginija Grinius; Cindy S-Y Lin; Matthew C Kiernan; James Howells; Meg J Jardine; Arun V Krishnan Journal: PLoS One Date: 2013-03-11 Impact factor: 3.240
Authors: Stefania S Grigoriou; Christina Karatzaferi; Christoforos D Giannaki; Gianna Patramani; Christina Vogiatzi; Georgia I Mitrou; Ioannis Stefanidis; Giorgos K Sakkas Journal: Int Urol Nephrol Date: 2022-07-05 Impact factor: 2.370
Authors: Ranjani N Moorthi; Simit Doshi; Linda F Fried; Sharon M Moe; Mark J Sarnak; Suzanne Satterfield; Ann V Schwartz; Michael Shlipak; Brittney S Lange-Maia; Tamara B Harris; Anne B Newman; Elsa S Strotmeyer Journal: Nephrol Dial Transplant Date: 2019-04-01 Impact factor: 5.992
Authors: Simit Doshi; Ranjani N Moorthi; Linda F Fried; Mark J Sarnak; Suzanne Satterfield; Michael Shlipak; Brittney S Lange-Maia; Anne B Newman; Elsa S Strotmeyer Journal: PLoS One Date: 2020-12-15 Impact factor: 3.240